|
|
 |
 |
Why It's Different |
|
Vivelle-Dot® uses an advanced technology to provide transdermal
estrogen therapy (ET).
Vivelle-Dot Offers:
-
Proven relief of moderate to severe menopause symptoms
and prevention of postmenopausal osteoporosis.1
-
Smaller total doses than pills. Transdermals achieve therapeutic levels with
smaller doses compared to oral therapy. This does not imply increased safety or
efficacy.
-
Smallest estrogen therapy patch available.
- Low incidence of skin irritation and side effects.
The skin metabolizes estradiol only to a small extent. In contrast, orally
administered estradiol is rapidly metabolized by the liver to estrone and it
conjugates, giving rise to higher circulating levels of estrone to estradiol.
Therefore, transdermal administration produces therapeutic levels of estradiol
with lower circulating levels of estrone and estrone conjugates and requires
smaller total doses than does oral therapy.
Vivelle-Dot delivers flexibility with 5 dosage strengths to meet individual
needs.
Vivelle-Dot 0.025 mg/day is indicated for the prevention of postmenopausal
osteoporosis only.
For women interested in the source of estrogen in their therapy, the estrogen in Vivelle-Dot (estradiol) is
chemically synthesized from a plant source. This does not mean Vivelle-Dot is safer or more effective than other
hormone therapies.
See full prescribing information PDF.
|
|
|
|